[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"steatotic-liver-disease-of-mixed-origin-metald\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:steatotic-liver-disease-of-mixed-origin-metald":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100585837",false,"NCT06907563","Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)","LOVE","Inclusion Criteria:\n\n* Previous Informed consent for cohort studies\n* \\> 18 years of age\n* Diagnosis of SLD (MASLD, MetALD, ALD)\n\nExclusion Criteria:\n\n* No consent for previous cohort studies\n* \\\u003C 18 years of age\n* No Diagnosis of SLD (MASLD, MetALD, ALD)","ALL","18 Years",{"count":18,"type":19},30000,"ESTIMATED","10 Years","OBSERVATIONAL","The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years. At current limited data on liver-specific and overall outcome in patients with MASLD, MetALD and ALD are available. Liver histology is the only accepted surrogate to reasonably likely predict outcomes in patients with non-cirrhotic liver disease and is currently used in regulatory trials. To overcome the limitations of liver biopsy and use validated non-invasive tests (NITs) to predict outcomes, the LOVE study will be conducted based on existing cohort studies in well pheno- and genotyped patients and will inform on the relevant outcomes based on baseline and ongoing biomarker assessment. The overarching goal is to qualify a NIT for patient identification and preventive measures in the regulatory context.",[24,25,26,27],"Steatotic Liver Disease","MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)","Steatotic Liver Disease of Mixed Origin (MetALD)","ALD - Alcoholic Liver Disease",[29,30,31,32,33,34,35,36],"MASH","SLD","NITs","MASLD","ALD","MetALD","Metabolism","Liver","NOT_YET_RECRUITING","2025-03-26",{"date":40,"type":41},"2025-04-02","ACTUAL",{"date":43,"type":19},"2025-04-15",{"date":45,"type":19},"2035-12-31",{"name":47,"class":48},"Universität des Saarlandes","OTHER",4,""]